SC
CSTL icon

SummitTX Capital’s Castle Biosciences CSTL Stock Holding History

SummitTX Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.65M Buy
67,033
+49,623
+285% +$1.63M 0.05% 339
2025
Q4 		$677K Sell
17,410
-27,590
-61% -$889K 0.02% 483
2025
Q3 		$1.02M Buy
+45,000
New +$914K 0.04% 380

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SummitTX Capital's CSTL Position: Q1 2026 in Review

SummitTX Capital increased its Castle Biosciences (CSTL) stake by 285% in Q1 2026, buying an estimated $1.63M and bringing the position to 67,033 shares worth $1.65M. The position accounts for 0.05% of the portfolio, ranked #339.

SummitTX Capital first reported a position in CSTL in Q3 2025 and has held it in 3 quarters since. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • SummitTX Capital held 67,033 shares of Castle Biosciences worth $1.65M as of Q1 2026.
  • SummitTX Capital bought 49,623 Castle Biosciences shares in Q1 2026, an estimated $1.63M.
  • Castle Biosciences made up 0.05% of SummitTX Capital's portfolio in Q1 2026, its #339 holding.
  • SummitTX Capital first reported a position in Castle Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.